Dermatologic Clinics 1995: Vol 13 Index

15 Pages·1995·2.6 MB·English

CUMULATIVE INDEX 1995
Volume 13
January GENODERMATOSES WITH MALIGNANT POTENTIAL, pages 1-243
April COSMETIC DERMATOLOGY, pages 245-503
July DERMATOEPIDEMIOLOGY, pages 505-716
October PSORIASIS, pages 717-955
Note: Page numbers of article titles are in boldface type.
Acitretin. See Systemic retinoids. Analgesia, in tumescent liposuction, 337
Acne, active, dermabrasion for, 315 Anesthesia, for chemical peels, 269
Acne scarring, dermabrasion for, 313-315 for dermabrasion, 320
Acquired melanocytic nevi, 595-603 for lower lid blepharoplasty, 409
analytic studies of, in adults, 596-599 for tumescent liposuction, 329-330
in children, 599, 601 for upper lid blepharoplasty, 400, 402
clinical definition and enumeration of, 596 Angioedema, drug-induced, ^5-686
Acrodermatitis continua, management of, 775 Angiofibromas, facial, in tuberous sclerosis complex,
Actinic keratosis, interferons for, 703-704 152
Acyclovir, for herpes simplex infection, in HIV Angiomyolipomas, renal, in tuberous sclerosis complex,
infection, 232-233 154, 156
for varicella-zoster virus, in HIV infection, 233 Angiotensin-converting enzyme inhibitors, and
Adenocarcinoma, gastrointestinal, in Peutz-Ieghers angioedema, 686
syndrome, 130 Ankylosing spondylitis, vs. psoriatic arthritis, 788
of colon, in Gardner's syndrome, 54 Anthralin, for psoriasis, 822-829
Adenoma sebaceum, in tuberous sclerosis complex, 152 clinical uses of, 824-829
Adenomas, pituitary, in Carney complex, 24 modification of Ingram regimen, 824-825
Adenomatous colon polyps, in Gardner's syndrome, 54, short-contact regimens, 825-827
55 with phototherapy, 827-829, 869
African iron overload, malignancies associated with, formulations and pharmacology of, 822-823
59-60 mechanism of action of, 823
Aging face, etiology of, 245 side effects of, 823-824
photoaging in, 245-247 Antibiotics, for Lyme disease, 539-540
cellular and molecular aspects of, 246-247 for psoriasis, 909-913
classification of, 247 choice of drug in, 911-913
clinical aspects of, 245-246 historical aspects of, 909-910
histology of, 247 laboratory results in, 910-911
treatment of, 245-261 pretherapy evaluation for, 910
alpha-hydroxy acids in, 248-249 prophylactic, in tumescent liposuction, 337
chemical peels in. See Chemical peels. Antibody-containing blood products, receipt of, as
cryopeels in, 253 contraindication to measles vaccination, 557-558
dermabrasion in. See Dermabrasion. Antigen-presenting cells, in psoriasis, 739-740
moisturizers in, 248 Antimalarials, for porphyrias, 141
soft tissue augmentation in. See Microlipoinjection. Aphthous stomatitis, in HIV infection, 237
sunscreens in, 248 Argon lasers, in cosmetic dermatology, 449
topical trehnoin in, 249, 251 Argon-pumped tunable dye lasers, in cosmetic
AIDS, Kaposi's sarcoma in. See Kaposi's sarcoma. dermatology, 450
Alcohol, role of, in psoriasis, 639-641, 718, 796 Arthritis, psoriatic. See Psoriatic arthritis.
Alexandrite lasers, in cosmetic dermatology, 455 with psoriasis, 725
Allergens, role of, in atopic dermatitis, 655 Arytenoid ethyl ester. See Systemic retinoids.
Allergic reactions, blepharoplasty and, 421 Ash leaf spots, in tuberous sclerosis complex, 151-152
Alpha-hydroxy acids, for aging face, 248-249 Astrocytomas, giant cell, in tuberous sclerosis complex,
Amenorrhea, systemic glucocorticosteroids and, 934-935 156, 160
Amyloidosis, lichen, in multiple endocrine neoplasia Ataxia-telangiectasia, 1-6
2/2A, 92 malignancies associated with, 2
941
942 CUMULATIVE INDEX 1995
Ataxia-telangiectasia (Continued) photographs in, 395-399
mucocutaneous stigmata of, 1-2 preoperahve, 390, 392-394
noncutaneous features of, 2 postoperative care for, 418
work-up for, 2-5 postoperaHve follow-up examination for, 418—427
Atherosclerosis, systemic glucocorticosteroids and, 934 preoperative instructions and release for, 399
Atopic dermatiHs, 649-657 preoperative marking for, 399-400
definition of, 649-653 preoperative preparation for, 399
applying hospital criteria in population setting, transconjunctival lower lid procedure in, 409
650-651 upper lid measurements for, 400
categoric or dimensional, 650 upper lid operative procedure in, 400, 402-409
diagnostic criteria for, 651 Blindness, blepharoplasty and, 423, 427
statistical, prognostic, operational, or clinical, 649- Bloch-Sulzberger syndrome, malignancies associated
650 with, 219-220
UK working party refinement of, 651-653 Blood cell effects, of systemic glucocorticosteroids, 935
descriptive epidemiology of, 653-656 Blood transfusions, and leishmaniasis, 516-517
environmental factors in, 654-655 Bloom's syndrome, 7-18
fetal and infant influences in, 654 clinical features of, 8-11
genetics in, 654 explanation for, 13-14
natural history in, 654 diagnosis of, 16
prevalence and morbidity in, 653-654 etiology of, 14-16
in Wiskott-Aldrich syndrome, 68 genetics in, 14-15
interferons for, 702 genomic instability in, 15-16
prevention of, 655-656 malignancies associated with, 12-13
Autologous collagen, microlipoinjection of. See management of, 16-18
Microlipoinjection. non-sun-sensitive lesions in, 12
Autologous fat, microlipoinjection of. See sun-sensitive facial lesions in, 11-12
Microlipoinjection. Blue nevi, in Carney complex, 20
Axillary freckling, in neurofibromatosis, 106-107 Bone marrow transplantation, for dyskeratosis
Azidothymidine, with interferons, for AIDS-related congenita, 37
Kaposi's sarcoma, 701 for Fanconi anemia, 46
Borrelia burgdorferi. See Lyme disease.
Bowenoid papulosis, human papillomavirus in, 568, 569
interferons for, 706
Bacillary angiomatosis, in HIV infection, 231-232 Bowing, lateral, blepharoplasty and, 422
Bacille Calmette-Guerin vaccination, against leprosy, Breast lesions, in Cowden syndrome, 28
533 Bums, role of, in skin cancer, 591
Bacterial infections, in chemical peels, 310
in HIV infection. See HIV infection.
in Wiskott-Aldrich syndrome, 68
Baker-Gordon solution, for chemical peels, 269-270 Cafe-au-lait macules, in neurofibromatosis, 105-106
Basal cell carcinoma, in nevoid basal cell carcinoma Calcipotriol, for psoriasis, 743, 835-841, 916
syndrome, 114 in HIV infection, 236
increased risk of, therapy for psoriasis and, 860 indications for, 838
interferons for, 702-703 mechanism of action of, 835-837
Bazex syndrome, basal cell carcinoma in, 120-121 safety of, 837-838
Beckwith-Wiedemann syndrome, 211-214 side effects of, 837
malignancies associated with, 214 with phototherapy, 836-837, 848, 918
mucocutaneous stigmata of, 212-214 for pustular psoriasis, 763
noncutaneous features of, 214 Camouflage therapy, in cosmetic dermatology, 467-472
Behqet's disease, interferons for, 706 application of, 464
Benign pigmented nevi, and melanoma, screening for, color blending in, 471
629 color correction in, 471
Benoxaprofen, for psoriasis, 917 duplication of skin imperfecHons in, 471-472
Betamethasone dipropionate, for psoriasis, 810 indications for, 467-468
Biologic response modifiers, for psoriasis, 745 limitations of, 471
Biopsies, liver, to monitor methotrexate therapy, for materials for, 468, 471
psoriasis, 880 patient evaluation for, 468
Birt-Hogg-Dube syndrome, malignancies associated patient goals in, 468
with, 214-216 principles of, 464
Blepharoplasty, 389-430 resources for, 472
indications for, 389 techniques for, 471
long-term results of, 427, 430 vs. makeup artists, 467
lower lid measurements for, 400 Cancer, of colon, in Birt-Hogg-Dube syndrome, 216
lower lid skin and muscle technique for, 417-418 of skin. See Skin cancer.
lower lid skin flap technique for, 409, 416-417 of thyroid, in Gardner's syndrome, 54
patient consultation for, 389 Candidiasis, in HIV infection, 234-235
patient evaluation for, 389-390 Cannulas, sizes of, for tumescent liposuction, 330
patient examination for, 390-395 Capsaicin, for psoria&is, 917
laboratory tests in, 395 Carbon dioxide lasers, in cosmetic dermatology,
ophthalmic, 394-395 448-449
CUMULATIVE INDEX 1995 943
Carcinoma, basal cell, in nevoid basal cell carcinoma postoperative care for, 281-282
syndrome, 114 preoperative preparation for, 278-279
increased risk of, therapy for psoriasis and, 860 results of, 282-283
interferons for, 702-703 trichloroacetic acid and phenol in, 263-276
colorectal, in Muir-Torre syndrome, 86 classification of agents for, 263
hepatocellular, in HLA-linked hemochromatosis, 59 deep peels, 265-271
in porphyrias. See Porphyrias. complications of, 271
medullary thyroid, in Birt-Hogg-Dube syndrome, informed consent for, 269
215-216 intraoperative monitoring and anesthesia for,
in multiple endocrine neoplasia 2/2A, 94 269
in multiple endocrine neoplasia 2B/3, 101-102 mixing and application of solution for, 269-270
periampullary, in Gardner's syndrome, 54 patient postoperative visits after, 270-271
squamous cell, increased risk of, therapy for psoriasis pretreatment of skin for, 269
and, 859-860 relative contraindications to, 268-269
interferons for, 703-704 taping and postoperative care for, 270
Cardiac fibromas, in nevoid basal cell carcinoma histology of, 274
syndrome, 119 historical aspects of, 263
Cardiac myxomas, in Carney complex, 22 medium-depth peels, 271-274
Cardiovascular abnormalities, in tuberous sclerosis patient selection for, 263-265
complex, 154 superficial peels, 274
Cardiovascular disease, increased risk of, therapy for vs. dermabrasion, 258
psoriasis and, 720 Chemicals, exposure to, and skin cancer, 590
Cardiovascular effects, of systemic glucocorticosteroids. Chemosis, blepharoplasty and, 419
See Systemic glucocorticosteroids. Chemosurgery, as contraindication to dermabrasion,
Carney complex, 19-26 317
mucocutaneous stigmata of, 20-21 vs. dermabrasion, 325-326
noncutaneous features of, 22-24 Chemotherapy, for psoriasis, 5-fluorouracil, 885-887,
cardiac myxomas, 22 915
myxoid mammary fibroadenomas, 23-24 hydroxyurea, 875, 885-886
pituitary adenomas, 24 mechanism of action of, 876
primary pigmented nodular adrenal disease, 22-23 mechlorethamine, 887
psammomatous melanotic schwannomas, 24 methotrexate. See Methotrexate.
testicular large cell calcifying Sertoli cell tumors, 24 6-thioguanine, 875, 886
Cataracts, juvenile posterior subcapsular, in thiotepa, 887
neurofibromatosis, 108 topical methotrexate, 887
systemic glucocorticosteroids and, 932 Chondrosarcoma, in Maffucci's syndrome, 74
Caustic solutions, in sclerotherapy, for varicose and Chromated glycerin, in sclerotherapy, for varicose and
telangiectatic veins, 441-442 telangiectatic veins, 442
Cellular effects, of systemic glucocorticosteroids. See Chromosome instability, in nevoid basal cell carcinoma
Systemic glucocorticosteroids. syndrome, 120
Cellular radiation sensitivity, in nevoid basal cell Chronic granulomatous disease, interferons for, 702
carcinoma syndrome, 120 Cigarette smoking, role of, in psoriasis, 641, 718
Central nervous system, malignancies of, in Gardner's Cirrhosis, methotrexate and, for psoriasis, 881, 919
syndrome, 54 Cleft lip and palate, in nevoid basal cell carcinoma
Cervical dysplasia, human papillomavirus in, 567-568 syndrome, 118
Chediak-Higashi syndrome, malignancies associated Clobetasol propionate, for psoriasis, 810
with, 67-68 Clotrimazole, for candidiasis, in HIV infection, 234
Cheeks, microlipoinjection of autologous fat in, 344 Cockayne's syndrome, vs. xeroderma pigmentosum,
Chemical peels, for aging face, 255, 257 194-195
complications of, 309-312 Collagen, autologous, microlipoinjection of. See
procedural side effects, 309-310 Microlipoinjection.
glycolic acid in, 285-307 Colon, adenocarcinoma of, in Gardner's syndrome, 54
acid application in, 291, 293 cancer of, in Birt-Hogg-Dube syndrome, 216
complicaHons of, 294-295 polyposis of, in Birt-Hogg-Dube syndrome, 215
histology of, 295 Colorectal carcinoma, in Muir-Torre syndrome, 86
indications for, 286-289 Complete blood count, to monitor methotrexate
mechanism of action of, 285 therapy, for psoriasis, 879
medications and combination therapies in, 290 Compression, after sclerotherapy, for varicose and
postoperative care for, 293-295 telangiectatic veins, 442
prepeel planning in, 289-290 Condyloma acuminatum, in HIV infection, 233-234
results of, 295, 297 interferons for, 699-701
skin preparation for, 290-293 Contact dermatitis, anthralin and, for psoriasis, 824
immediately prepeel, 291 occupational. See Occupational contact dermatitis.
two to four weeks prior to peel, 290-291 topical corticosteroids and, for psoriasis, 812
with other peeling agents, 295 Contact sensitization, in sunscreen intolerance, 473-475,
Jessner's-trichloroacetic acid in, medium-depth 477-478
peels, 277-283 Contact urticaria, in sunscreen intolerance, 478
complications of, 282-283 Contour defects, blepharoplasty and, 421-422
method for, 277-282 Copper bromide lasers, in cosmetic dermatology, 451,
patient consultation for, 277-278 456
944 CUMULATIVE INDEX 1995
Comeal irritation, blepharoplasty and, 419 with phototherapy, 871, 904
Corticosteroids, systemic. Sw Systemic corticosteroids. for psoriatic arthritis, 791
topical. See Topical corticosteroids. Cysts, epidermoid, in Gardner's syndrome, 51-52
Cosmetic dermatology, blepharoplasty in. See mesenteric, in nevoid basal cell carcinoma syndrome,
Blepharoplasty. 119
camouflage therapy in. See Camouflage therapy. renal, in tuberous sclerosis complex, 156
chemical peels in. See Chemical peels.
cosmetics in. See Cosmetics.
dermabrasion in. See Dermabrasion.
for aging face. See Aging face. Dardour flaps, in hair transplantation, 383
hair transplantation in. See Hair transplantation. Dental abnormalities, in Gardner's syndrome, 53
lasers in. See Lasers. Depigmentation, chemical peels and, 271
microinjection of autologous collagen in. See Dermabrasion, 313-327
Microlipoinjection. adjunctive procedures with, 323-325
microlipoinjection of autologous fat in. See anesthesia for, 320
Microlipoinjection. complications of, 322-323
sclerotherapy in. See Sclerotherapy. contraindications to, 317-318
sunscreen intolerance in. See Sunscreen intolerance. for acne scarring, 313-315
tumescent liposuction in. See Tumescent liposuction. for active acne, 315
Cosmetics, in postsurgical patient, 461-465 for aging face, 257-261
camouflage therapy in. See Camouflage therapy. vs. chemical peels, 258
eye cosmetics in, 463 for rhytides, 315-316
facial foundations in, 462 for tattoo removal, 316
lip cosmetics in, 463 for vitiligo, 316
powders and blushers in, 463 indications for, 313
removal of, 463-464 instrumentation for, 319-320
skin care and, 461-462 office and staffing considerations in, 320
incisional wounds, 461 patient education and informed consent for, 318
large surface area wounds, 461-462 patient selection for, 313
undercover foundations in, 463 physician qualifications and technical skills for, 318
Cowden syndrome, 27-31 postoperative care for, 321-322
breast lesions in, 28 preoperative planning for, 318-319
diagnosis of, 27 repeat, 326
eye lesions in, 29 techniques for, 321
gastrointestinal lesions in, 29 vs. chemosurgery or laser surgery, 325-326
genitourinary tract abnormalities in, 29 Dermatitis, atopic. See Atopic dermatitis.
management of, 30-31 occupational contact. See Occupational contact derma¬
mucocutaneous stigmata of, 27-28 titis.
pathophysiology of, 30 seborrheic, in HIV infection, 235-236
skeletal abnormalities in, 29 Dermatoepidemiology, dermatologic health services
thyroid gland lesions in, 28 research in, 689-695
Cross-sensitization reactions, in sunscreen intolerance, avoidance of bias in, 693-694
475-476 data measurement in, 693
Cryopeels, for aging face, 257 data sources in, 693
Cushing's syndrome, in Carney complex, 22-23 generalizability in, 694
topical corticosteroids and, for psoriasis, 811 patient sample in, 693
Cutaneous effects, of systemic glucocorticosteroids. See patient's perspective on, 692
Systemic glucocorticosteroids. physician's perspective on, 690-692
Cutaneous malignant melanoma, 605-612 developing and measuring outcome, 690-692
genetic epidemiology of, 605-609 profiling types of care, 690
candidate gene pl6 in, 607 research question in, 693
chromosome Ip in, 606 society's perspective on, 692
chromosome 9p in, 606-607 study design in, 693
complexities of, 607-609 of acquired melanocytic nevi. See Acquired melanocytic
description, 605 nevi.
future studies in, 609 of atopic dermatitis. See Atopic dermatitis.
principles of linkage analysis, 605-606 of cutaneous malignant melanoma. See Cutaneous ma¬
public health issues in, 609^10 lignant melanoma.
education, 610 of drug reactions. See Drug reactions.
screening and management, 609-610 of epidermolysis bullosa. See Epidermolysis bullosa.
Cyclosporine, for erythrodermic psoriasis, 769 of human papillomaviruses. See Human papillomavi¬
for psoriasis, 743-744, 897-907, 917, 920 ruses.
dosage and schedule for, 899-900 of Kaposi's sarcoma. See Kaposi's sarcoma.
follow-up of, 905 of leishmaniases. See Leishmaniases.
indications for, 903-905 of leprosy. See Leprosy.
mechanism of action of, 897, 899 of Lyme disease. See Lyme disease.
pharmacokinetics of, 899 of measles. See Measles.
pretherapy evaluation for, 904-905 of melanoma. See Melanoma.
side effects of, 900-903 of occupational contact dermatitis. See Occupational
with methotrexate, 884, 903-904 contact dermatitis.
CUMULATIVE INDEX 1995 945
Dermatoepidemiology (Continued) clinical outcomes in, 662
of psoriasis. See Psoriasis. differential surveillance in, 660
of skin cancer. See Skin cancer. misclassification bias in, 660-661
terminology in, 697-698 natural history in, 662
Dermatophytosis, in HIV infection, 235 observational or informational bias in, 661
Desmoid tumors, in Gardner's syndrome, 52 phenotypes and genotypes in, 662-663
Detergent solutions, in sclerotherapy, for varicose and prevalence and incidence in, 662
telangiectatic veins, 440-441 quality of laboratory tests in, 661-662
Diabetes mellitus, in Bloom's syndrome, 9 selection bias in, 659-660
Diepoxybutane test, for Fanconi anemia, 42 socioeconomic impact in, 662
Diet, role of, in psoriasis, 641-642, 718-719 Erythema, anthralin and, for psoriasis, 823-824
in skin cancer, 590-591 blepharoplasty and, 419, 421
Dihydrofolate reductase inhibitors, for psoriasis, with chemical peels and, 311
methotrexate, 885 dermabrasion and, 322
DNA repair, for Rothmund-Thomson syndrome, 148 Erythrodermic psoriasis, 763-769
Doppler ultrasound, in physical examination, of clinical features of, 764
varicose and telangiectatic veins, 435-437 histopathology of, 764, 768
Drug reactions, cutaneous, 681-688 provocative factors in, 768
angioedema, 685-686 treatment of, 768-769
rates of, 682-683 systemic retinoids in, 892-893
serum sickness and serum sickness-like reactions, with psoriasis vulgaris, 763
685 Ethanolamine oleate, in sclerotherapy, for varicose and
sources of information on, 681-682 telangiectatic veins, 441
toxic epidermal necrolysis, 683-684 Ethyl chloride, in anesthesia, for dermabrasion, 320
Dry eye syndrome, blepharoplasty and, 422 Etretinate, for psoriasis. See Systemic retinoids.
Duncan's disease, malignancies associated with, 69-70 Excited skin syndrome, in patch testing, for sunscreen
Duplex ultrasound, in physical examination, of varicose intolerance, 478
and telangiectatic veins, 439 Extender of Frechet, in hair transplantation, 384-385
Dyskeratosis congenita, 33-39 Eyelids, chemical peels of, Jessner's-trichloroacetic acid
clinical evaluation of, 37 in, 281
cutaneous stigmata in, 33-34
malignancies associated with, 35-37
management of, 37-38
noncutaneous features of, 34-37 Face lift, as contraindication to chemical peels, for aging
hematologic, 35 face, 269
physical, 34-35 Facial angiofibromas, in tuberous sclerosis complex, 152
vs. Fanconi anemia, 37 Facial hemiatrophy, microlipoinjection of autologous fat
Dysplastic nevi, and melanoma, screening for, 629 for, 345
Dystrophic nails, in dyskeratosis congenita, 34 Familial atypical multiple mole melanoma syndrome,
malignancies associated with, 216-218
Familial melanoma. See Cutaneous malignant melanoma.
Fanconi anemia, 41-49
Ear abnormalities, in Beckwith-Wiedemann syndrome, bone marrow transplantation for, 46
213 diepoxybutane test for, 42
Ecchymosis, blepharoplasty and, 419 international registry of, patient features in, 42-46
Ectropion, blepharoplasty and, 419, 422 congenital malformations, 43-45
Edema, blepharoplasty and, 421 hematologic abnormalities, 45-46
systemic glucocorticosteroids and, 934 molecular studies of, 46-47
Electrodesiccation, with dermabrasion, 325 umbilical cord blood transplantation for, 46
Elliot flaps, in hair transplantation, 382 vs. dyskeratosis congenita, 37
Enchondromas, in Maffucci's syndrome. See Maffucci's Fat, autologous, microlipoinjection of. See
syndrome. Microlipoinjection.
Endocrine overactivity, in Carney complex. See Carney Female sex hormones, role of, in skin cancer, 590
complex. Fetal effects, of systemic glucocorticosteroids, 935
Endothelial cells, in psoriasis, 732, 741-742 Fetal rhabdomyomas, in nevoid basal cell carcinoma
Enthesopathy, in psoriatic arthritis, 782-783, 785, syndrome, 120
789-790 Fibrel. See Microlipoinjection, of autologous collagen.
Entropion, blepharoplasty and, 422 Fibroadenomas, myxoid mammary, in Carney complex,
Epidermal atrophy, topical corticosteroids and, for 23-24
psoriasis, 812 Fibroblasts, in psoriasis, 731-732
Epidermodysplasia verruciformis, human Fibrofolliculomas, in Birt-Hogg-Dube syndrome, 215
papillomavirus in, 564 Fibromas, cardiac, in nevoid basal cell carcinoma
Epidermoid cysts, in Gardner's syndrome, 51-52 syndrome, 119
Epidermolysis bullosa, 659-670 ovarian, in nevoid basal cell carcinoma syndrome,
and skin cancer, 666-667 119-120
disease registries of, 663-664 perifollicular, in Birt-Hogg-Dube syndrome, 215
National Epidermolysis Bullosa Registry, 664-667 ungual, in tuberous sclerosis complex, 152
examples of data from, 665-667 Fibroplasia, impaired, systemic glucocorticosteroids
epidemiology of, 659-663 and, 935
classification and subclassification in, 661 Fibrotic diseases, interferons for, 707-708
946 CUMULATIVE INDEX 1995
FK506, for psoriasis, 744, 917 Werner's syndrome. See Werner's syndrome.
for psoriatic arthritis, 791 xeroderma pigmentosum. See Xeroderma pigmentosum.
Flaps, in hair transplantation. See Hair transplantation. Genomic instability, in Bloom's syndrome, 15-16
Flashlamp-pumped pulsed dye lasers, in cosmetic Giant cell astrocytomas, in tuberous sclerosis complex,
dermatology, 450-451, 456 156, 160
5-Fluorouracil, for psoriasis, 886-887, 915 Glabellar furrows, microlipoinjection of autologous fat
with methotrexate, 885 for, 343-344
Follicular mucinosis, interferons for, 706 Glaucoma, systemic glucocorticosteroids and, 932-933
Foscamet, for herpes simplex infection, in HIV Gliomas, optic nerve, in neurofibromatosis, 108-109
infection, 232 Glucocorticosteroids, systemic. See Systemic
Freckling, axillary, in neurofibromatosis, 106-107 glucocorticosteroids.
Freons, in anesthesia, for dermabrasion, 320 Glycolic acid, in chemical peels. See Chemical peels.
Frequency-doubled Nd;YAG lasers, in cosmetic Goeckerman regimen, for psoriasis, 820-822
dermatology, 456 Grafts, in hair transplantation. See Hair transplantation.
Fumaric acid esters, for psoriasis, 920 island. See Island grafts.
Fungal infections, in HIV infection, 234-235 Griseofulvin, for dermatophytosis, in HIV infection, 235
Growth factor therapy, for dyskeratosis congenita, 37
Growth retardation, systemic glucocorticosteroids and,
931-932
Gardner's syndrome, 51-56 Guttate psoriasis, clinical features of, 751-752
cutaneous stigmata in, 51-52 histopathology of, 753
evaluation, management, and follow-up of, 54-55 HLA markers in, 752-753
malignancies associated with, 54 response to therapy in, 753, 755
noncutaneous features of, 52-54 Gynecologic effects, of systemic glucocorticosteroids.
Gastrointestinal effects, of systemic glucocorticosteroids. See Systemic glucocorticosteroids.
See Systemic glucocorticosteroids.
Gastrointestinal ganglioneuromatosis, in multiple
endocrine neoplasia 2B/3, 100
Hair transplantation, 363-387
GastrointesHnal lesions, in Cowden syndrome, 29
grafting in, 365-377
Gastrointestinal malignancies, in Peutz-Jeghers
avoiding compression on, 371
syndrome, 129-131
combination micrografting with strip harvesting in,
Genital herpes simplex infection, interferons for, 705
368, 370
Genital human papillomavirus. See Human
grading of, 374
papillomaviruses.
placing grafts in, 376-377
Genitourinary tract abnormalities, in Cowden
planning for session size in, 371-372
syndrome, 29
pre- and postoperative instructions in, 370-371
Genodermatoses, ataxia-telangiectasia. See Ataxia-
producing recipient site for, 376
telangiectasia.
removing epidermis in, 374-375
Beckwith-Wiedemann syndrome. See Beckwith-Wiede-
standard micrografting session in, 366
mann syndrome. strip harv'esting technique in, 372-375
Birt-Hogg-Dube syndrome, 215-216 hair-bearing flaps in, 380-385
Bloom's syndrome. See Bloom's syndrome. Dardour flap, 383
Carney complex. See Carney complex. Elliot flap, 382
Cowden syndrome. See Cowden syndrome. extender of Frechet, 384-385
dyskeratosis congenita. See Dyskeratosis congenita. instrumentation advances in, 385
familial atypical multiple mole melanoma syndrome, Juri flap, 381-382
216-218 Nataf flap, 382-383
Fanconi anemia. See Fanconi anemia. newer flaps worldwide, 383-384
Gardner's syndrome. See Gardner’s syndrome. historical aspects of, 363
hereditary tylosis, 218-219 ideal candidates for, 363-365
HLA-linked hemochromatosis. See HLA-linked hemoch¬ recipient site for, 365
romatosis. scalp reduction in, 377-380
immunodeficiency syndromes. See Immunodeficiency bilateral lateral technique for, 380
syndromes. stretch back and long-term benefits of, 378-379
incontinentia pigmenti, 219-220 Hamartomas, retinal, in tuberous sclerosis complex, 152,
Maffucci's syndrome. See Maffucci's syndrome. 154
Muir-Torre syndrome. See Muir-Torre syndrome. Hamartomatous polyps, in Peutz-Jeghers syndrome, 128
multiple endocrine neoplasia 2/2A. See Multiple endo¬ Hands, microlipoinjection of autologous fat in, 345
crine neoplasia IHA. papillomas of, 563
multiple endocrine neoplasia 2B/3. See Multiple endo¬ Hemangioma, interferons for, 706
crine neoplasia 2B/3. Hematologic abnormalities, in dyskeratosis congenita,
neurofibromatosis. See Neurofibromatosis. 35
nevoid basal cell carcinoma syndrome. See Nevoid in Fanconi anemia, 45-^6
basal cell carcinoma syndrome. Hematologic effects, of systemic glucocorticosteroids.
Peutz-Jeghers syndrome. See Peutz-Jeghers syndrome. See Systemic glucocorticosteroids.
porphyrias. See Porphyrias. Hematomas, blepharoplasty and, 422—423
Rothmund-Thomson syndrome. See Rothmund-Thom- Hemihypertrophy, in Beckwith-Wiedemann syndrome,
son syndrome. 214
supernumerary nipples, 220-226 Hemochromatosis, HLA-linked. See HLA-linked
tuberous sclerosis. See Tuberous sclerosis complex. hemochromatosis.
CUMULATIVE INDEX 1995 947
Heparsol, in sclerotherapy, for varicose and Hyperlipidemia, systemic glucocorticosteroids and, 934
telangiectatic veins, 441 Hyperpigmentation, chemical peels and, 271, 294-295,
Hepatitis infections, as contraindication to 309
dermabrasion, 317-318 dermabrasion and, 323
Hepatocellular carcinoma, in HLA-linked Hypertension, cyclosporine and, for psoriasis, 902
hemochromatosis, 59 systemic glucocorticosteroids and, 934
in porphyrias. See Porphyrias. Hypertonic dextrose and saline, in sclerotherapy, for
Hereditary tylosis, malignancies associated with, varicose and telangiectatic veins, 441
218-219 Hypertonic saline, in sclerotherapy, for varicose and
Herpes simplex hepatitis, methotrexate and, for telangiectatic veins, 441
psoriasis, 882 Hypertrophic scarring, chemical peels and, 294, 311
Herpes simplex infections, as contraindication to dermabrasion and, 323
chemical peels, for aging face, 268 Hypoglycemia, in Beckwith-Wiedemann syndrome, 214
as contraindication to dermabrasion, 317 Hypogonadism, in nevoid basal cell carcinoma
genital, interferons for, 705 syndrome, 118
in chemical peels, 310 Hypomelanotic macules, in tuberous sclerosis complex,
in HIV infecHon, 232-233 151-152
Herpes zoster, interferons for, 705-706 Hypopigmentation, chemical peels and, 271, 295, 309
methotrexate and, for psoriasis, 882 dermabrasion and, 323
HIV infection, as contraindication to dermabrasion, Hypothalamic-pituitary-adrenal axis, and systemic
317-318 glucocorticosteroids, 927, 936-937
as contraindication to measles vaccination, 557
skin diseases in, 231-238
bacterial infections, 231-232
bacillary angiomatosis, 231-232 Immune system, compromised, as contraindication to
Staphylococcus aureus infections, 231 measles vaccination, 557
syphilis, 232 Immunocompetent patients, human papillomavirus in,
papulosquamous diseases, 235-237 564, 566
aphthous stomatitis, 237 Immunocompromised patients, human papillomavirus
generalized pruritus, 237 in, 564
papular dermatoses, 236-237 skin cancer in, 590
psoriasis and Reiter's disease, 236, 719, 726 Immunodeficiency, in ataxia-telangiectasia, 3
seborrheic dermatitis, 235-236 in Bloom's syndrome, 9-10
viral infections, 232-235 Immunodeficiency syndromes, 65-71
herpes simplex, 232-233 Chediak-Higashi syndrome, 67-68
human papillomavirus, 233-234 panhypoglobulinemia syndromes, 65-67
molluscum contagiosum, 233 Wiskott-Aldrich syndrome, 68-69
mucocutaneous fungal infections, 234-235
X-linked lymphoproliferative disorder, 69-70
oral hairy leukoplakia, 233
Immunologic effects, of PUVA therapy, for psoriasis,
varicella-zoster virus, 233
858-859
with leprosy, 533
Immunomodulatory agents, for psoriasis, 920
with porphyrias, 139-140
Immunosuppression, systemic glucocorticosteroids and,
with psoriatic arthritis, 781, 789, 791
935
HLA-linked hemochromatosis, 57-63
Immunotherapy, for psoriasis. See Psoriasis.
diagnosis and treatment of, 60-62
Incontinentia pigmenti, malignancies associated with,
historical asjjects of, 57-58
219-220
incidence of, 57
Infections, bacterial, in Wiskott-Aldrich syndrome, 68
malignancies associated with, 59-60
chemical peels and, 271, 294, 310
mucocutaneous stigmata of, 58-59
in HIV infection. See HIV infection.
noncutaneous features of, 59
methotrexate and, for psoriasis, 882
pathogenesis of, 58
role of, in psoriasis, 641, 718, 725-726, 741
Hormones, female sex, role of, in skin cancer, 590
Infertility, methotrexate and, for psoriasis, 882
Human imm.unodeficiency virus infection. See HIV
Ingram regimen, for psoriasis, 824-825
infection.
Insulin-like growth factor 2, in Beckwith-Wiedemann
Human papillomaviruses, 561-574
biologic characteristics of, affecting epidemiology, 562 syndrome, 212
detection of, 561-562 Interferons, dermatologic uses of, 699-711
genital, 566-570 FDA-approved, 699-702
frequency of, 566-567 AID^related Kaposi's sarcoma, 701
in children, 568-570 chronic granulomatous disease, 702
natural history and relation to malignancy of, 567- condyloma acuminatum, 699-701
568 for human papillomavirus infection, in HIV
in epidermodysplasia verruciformis, 564 infection, 234
in HIV infection, 233-234 non-FDA-approved, 702-708
in immunocompetent patients, 564, 566 actinic keratosis and squamous cell carcinoma,
in immunosuppressed patients, 564 703-704
nongenital cutaneous, 562-564 atopic dermatitis, 702
Hydroxyurea, for psoriasis, 875, 885-886 basal cell carcinoma, 702-703
for pustular psoriasis, 762 Behqet's disease, 706
Hyperglycemia, systemic glucocorticosteroids and, follicular mucinosis, 706
933-934 genital herpes simplex, 705
f
948 CUMULATIVE INDEX 1995
Interferons (Continued) argon lasers, 449
hemangioma, 706 argon-pumped tunable dye lasers, 450
herpes zoster, 705-706 carbon dioxide lasers, 448-449
keratoacanthoma, 705 copper bromide lasers, 451
lupus erythematosus, 706 for pigmented lesions, 455-456
melanoma, 704-705 frequency-doubled Nd:YAG lasers, 456
mycosis fungoides, 705 krypton lasers, 451
psoriatic arthritis, 706-707 Nd:YAG lasers, 454-455
systemic sclerosis and fibrotic diseases, 707-708 physics of, 447
verruca vulgaris/bowenoid papulosis, 706 Q-switched lasers, 451, 453-455
Intraocular pressure, increase in, blepharoplasty and, ruby lasers, 453-454
423 tissue interaction with, 447-448
Ionizing radiation, role of, in skin cancer, 590 visible light lasers, 449-451
Iron overload. See HLA-linked hemochromatosis. yellow light lasers, 449-451
Irritant solutions, in sclerotherapy, for varicose and Leishmaniases, 505-523
telangiectatic veins, 441-442 clinical features of, 507-508
Island grafts, to close wound defects, 483-498 cutaneous, 507-508
elliptical primary defect, 490, 492 visceral, 508
irregular primary defect, 483-484, 487 diagnosis of, 508-509
named? geometric primary defect, 487, 490, 492 epidemiologic triangle in, 511-513
trapezoidal primary defect, 490 anthroponoses, 512
triangular primary defect, 487 New World, 512
unusual primary defect, 492, 498 Old World, 512
Isotretinoin, for psoriasis, with PUVA therapy, 871 reservoir hosts, 511
prior use of, as contraindication to dermabrasion, 317 sand fly vector, 513
Itraconazole, for candidiasis, in HIV infection, 235 geographic distribution of, 510-511
incidence and prevalence of, 509-510
life cycle of, 505-506
modes of transmission in, 516-517
Jessner's-trichloroacetic acid, in chemical peels. See prevention and control of, 518
Chemical peels. risk factors for, 513, 515-516
Jordan light, in Goeckerman therapy, for psoriasis, 821 taxonomy of, 5-6
Juri flaps, in hair transplantation, 381-382 treatment of, 509
Juvenile posterior subcapsular cataracts, in tropism in, 506-507
neurofibromatosis, 108 Lentigines, in Carney complex, 20
Leprosy, 525-536
classificaHon of, 526
clinical features of, 525-528
Kaposi's sarcoma, 575-582 detection rates in, 532-533
AIDS-related, 575, 577-581 epidemiology of, 528-532
epidemiologic variables in, 578-580 future trends in, 533-535
clustering by person, place, and time, 579-580 nerve damage in, 527-528
person, 578-579 treatment of, 532
place, 579 vaccination against, 533
time, 579 Leucovorin, with methotrexate, for psoriasis, 885
etiology of, 580-581 Leucovorin rescue, for methotrexate overdose, in
interferons for, 701 psoriasis, 883
historical aspects of, 575 Leukopenia, methotrexate and, for psoriasis, 881
Karyotyping, of ataxia-telangiectasia, 3 Leukoplakia, in dyskeratosis congenita, 34
Keloids, interferons for, 707-708 Lichen amyloidosis, in multiple endocrine neoplasia
Keratinocytes, in psoriasis, 731, 740 2/2A, 92
Keratoacanthomas, in Muir-Torre syndrome, 81-82 Lipids, elevation of, systemic retinoids and, for
interferons for, 705 psoriasis, 894
Keratoconjunctivitis sicca, blepharoplasty and, 422 Liposuction, tumescent. See Tumescent liposuction.
Keratocysts, odontogenic, in nevoid basal cell carcinoma Lips, microlipoinjection of autologous fat in, 344
syndrome, 115-116 upper, dermabrasion of, 259-261
Ketoconazole, for Ccmdidiasis, in HIV infection, 235 Lisch nodules, in neurofibromatosis, 108
for dermatophytosis, in HIV infection, 235 Liver biopsies, to monitor methotrexate therapy, for
Kidney abnormalities, in nevoid basal cell carcinoma psoriasis, 880
syndrome, 118 Liver disease, methotrexate and, for psoriasis, 881-882
Kidney disease, cyclosporine and, for psoriasis, 902-903 systemic retinoids and, for psoriasis, 894
Koebner reaction, in psoriasis, 726-727 Liver function tests, to monitor methotrexate therapy,
Krypton lasers, in cosmetic dermatology, 451, 456 for psoriasis, 879-880
Lung disease, methotrexate and, for psoriatic arthritis,
790-791
Lupus erythematosus, interferons for, 706
Lagophthalmos, blepharoplasty and, 422 Lupus profundus, microlipoinjection of autologous fat
Laser surgery, vs. dermabrasion, 325-326 for, 344-345
Lasers, in cosmetic dermatology, 447-460 Lyme disease, 537-551
alexandrite lasers, 455 diagnosis of, 539
CUMULATIVE INDEX 1995 949
Lyme disease (Continued) historical aspects and efficacy of, 876-877
epidemiology of, 540-546 in HIV infection, 236
alternate vectors, 542 indicahons for, 877
disease emergence, 545-546 mechanism of action of, 876
distribution of disease and its tick vectors, 540, 542 monitoring of, 879-880
risk factors, 546 patient selection for, 878
surveillance statistics, 543-545 pharmacology of, 877
transmission of spirochete, 540 pretherapy evaluation for, 878
vertebrate hosts, 542-543 side effects of, 880-883
etiology of, 537-538 antidote to, 883
host-parasite interaction in, 538-539 drug interactions, 882-883
prevention of, 546-547 hematologic, 881
treatment of, 539-540 hepaHc, 881-882
Lymphoreticular malignancies, in Wiskott-Aldrich infectious, 882
syndrome, 69 infertility, 882
topical, 887, 915
with cyclosporine, 884, 903-904
with dihydrofolate reductase inhibitors, 885
Macroglossia, in Beckwith-Wiedemann syndrome, with 5-fluorouracil, 885
212-213 with leucovorin, 885
Maffucci's syndrome, 73-78 with phototherapy, 848, 869-870, 883-884
malignancies associated with, 74 with systemic retinoids, 884
mucocutaneous stigmata of, 73 for psoriatic arthritis, 790
noncutaneous features of, 73-74 for pustular psoriasis, 762
work-up and follow-up of, 74-77 8-Methoxypsoralen. See PUVA therapy.
Measles, 553-559 Microlipoinjection, of autologous collagen, for dermal
clinical features of, 553-554 defects, 347-350
diagnosis of, 554 complications of, 349
epidemiology of, 554-555 Fibrel in, 251, 353-361
prevention of, 555-556 adverse reactions to, 359
vaccination against, 556-557 contraindications to, 356
adverse reactions to, 557 Fibrel kit in, 355-356
contraindications to, 557-558 future uses of, 359-360
improvements in, 558 historical aspects of, 353-354
Mechlorethamine, for psoriasis, 887 indications for, 356
Medullary thyroid carcinoma, in Birt-Hogg-Dube injection techniques for, 356-358
syndrome, 215-216 mechanism of action of, 354-355
in multiple endocrine neoplasia 2/2A, 94 results of, 358-359
in multiple endocrine neoplasia 2B/3, 101-102 skin test procedure in, 356
Medulloblastoma, in nevoid basal cell carcinoma historical aspects of, 347-348
syndrome, 118-119 longevity of, 349-350
Melanoma, cutaneous malignant. See Cutaneous technique for, 348-349
malignant melanoma. of autologous fat, for aging face, 251, 255
in xeroderma pigmentosum, 188-189 for dermal defects, 339-347
increased risk of, therapy for psoriasis and, 720 complications of, 345
interferons for, 704-705 historical aspects of, 339
screening for, 623-634 indications for, 343-345
definitions and applications of, 624-625 longevity of, 345, 347
education and early detection programs in, 625-626 microlipoextraction of fat in, 339-340
international, 631-632 reimplantation of fat in, 342-343
in high-risk people, 629-630 treatment of collected fat in, 340
mass screening, 626-628 Milia, blepharoplasty and, 421
educational effects of, 627-628 chemical peels and, 310
risk profiles in, 627 dermabrasion and, 323
visual examination in, 626-627 in nevoid basal cell carcinoma syndrome, 114
yield of, 626 Moisturizers, for aging face, 248
outcome measures in, 625 Molecular studies, of Fanconi anemia, 46-47
professional education in, 630-631 Molluscum contagiosum, in HIV infection, 233
self-screening, 628-629 Mometasone furoate, for psoriasis, 916
Melolabial furrows, microlipoinjection of autologous fat Morphea, microlipoinjection of autologous fat for,
for, 344 344-345
Mesenteric cysts, in nevoid basal cell carcinoma Mucosal neuromas, in multiple endocrine neoplasia
syndrome, 119 2B/3, 99
Metabolic effects, of systemic glucocorticosteroids. See Muir-Torre syndrome, 79-89
Systemic glucocorticosteroids. cutaneous stigmata in, 81-82
Methotrexate, for erythrodermic psoriasis, 768 historical aspects of, 79-81
for psoriasis, 743, 817-818, 875-890, 919 incidence of, 79
contraindications to, 878 malignancies associated with, 86
current uses of, 877-878 noncutaneous features of, 82, 86
dosage and schedule for, 879 work-up and follow-up of, 87
950 CUMULATIVE INDEX 1995
Multiple endocrine neoplasia 2/2A, 91-97 musculoskeletal radiographic findings in, 116-118
mucocutaneous stigmata of, 92 odontogenic keratocysts in, 115-116
noncutaneous features of, 92-95 ovarian fibromas in, 119-120
Multiple endocrine neoplasia 2B/3, 99-103 palmar and plantar pits in, 115
diagnosis and screening of, 102-103 Nevus flammeus, facial, in Beckwith-Wiedemann
malignancies associated with, 101-102 syndrome, 213-214
mucocutaneous stigmata of, 99-100 Nitrogen mustard, for psoriasis, 887
noncutaneous features of, 100-101 Nonmelanoma skin cancer, PUVA therapy and, for
Multiple hamartoma syndrome. See Cowdeti syndrome. psoriasis, 859-860
Musculoskeletal abnormalities, in multiple endocrine Nonsolar ultraviolet radiation, role of, in skin cancer,
neoplasia 2B/3, 100-101 589-590
Musculoskeletal effects, of systemic glucocorticosteroids. Nonsteroidal anti-inflammatory drugs, for psoriatic
See Systemic glucocorticosteroids. arthritis, 789-790
of systemic retinoids, for psoriasis, 894
Mycophenolic acid, for psoriasis, 875-876
Mycosis fungoides, interferons for, 705
Myopathy, systemic glucocorticosteroids and, 932 Obesity, systemic glucocorticosteroids and, 934
Myxomas, in Carney complex. See Carney complex. Obstetric effects, of systemic glucocorticosteroids. See
Systemic glucocorticosteroids.
Occupational contact dermatitis, 671-680
epidemiology of, 671-673
Nail disease, with psoriatic arthritis, 785-786 problems in assessing, 672-673
Nails, dystrophic, in dyskeratosis congenita, 34 etiology of, 677
psoriasis of, 772-77'S population at risk for, 675-677
Nasolabial furrows, microlipoinjection of autologous fat prevention of, 677-678
for, 344 prognosis for, 677
Nataf flaps, in hair transplantation, 382-383 public health issues in, 673-675
Nd;YAG lasers, in cosmetic dermatology, 454-455 United States Bureau of Labor Statistics data on, 673
Neoplastic effects, of PUVA therapy, for psoriasis, workers' compensation data on, 674-675
859-860 Ocular abnormalities, in Cowden syndrome, 29
Nervous system effects, of systemic in dyskeratosis congenita, 34
glucocorticosteroids. See Systemic in Gardner's syndrome, 53-54
glucocorticosteroids. in multiple endocrine neoplasia 2B/3, 99-100
Neurofibromas, in neurofibromatosis, 107-108 in nevoid basal cell carcinoma syndrome, 118
Neurofibromatosis, 105-111 in Rothmund-Thomson syndrome, 146
malignancies associated with, 108-110 in tuberous sclerosis complex, 152, 154
optic nerve gliomas, 108-109 Ocular apraxia, in ataxia-telangiectasia, 2
peripheral nerve sheath tumors, 109 Odontogenic keratocysts, in nevoid basal cell carcinoma
pheochromocytoma, 110 syndrome, 115-116
spinal tumors, 109 Ophthalmologic effects, of PUVA therapy, for psoriasis,
vestibular schwarmomas, 109 858
mucocutaneous stigmata of, 105-108 of systemic glucocorticosteroids. See Systemic glucocor¬
axillary freckling, 106-107 ticosteroids.
cafe-au-lait macules, 105-106 of systemic retinoids, for psoriasis, 895
neurofibromas, 107-108 Optic nerve gliomas, in neurofibromatosis, 108-109
noncutaneous features of, 108 Oral abnormalities, in dyskeratosis congenita, 34
work-up and follow-up of, 110-111 in Rothmund-Thomson syndrome, 145
Neurologic abnormalities, in tuberous sclerosis Oral cavity, papillomas of, 564
complex, 156 Oral commissures, microlipoinjection of autologous fat
in xeroderma pigmentosum, 189-190 for, 344
Neuromas, mucosal, in multiple endocrine neoplasia Oral hairy leukoplakia, in HIV infection, 233
2B/3, 99 Osmotic solutions, in sclerotherapy, for varicose and
Neurons, in psoriasis, 742 telangiectatic veins, 441
Neuropsychiatric effects, of systemic Osteomas, in Gardner's syndrome, 52-53, 54-55
glucocorticosteroids, 936 Osteonecrosis, systemic glucocorticosteroids and,
Nevi, acquired melanocytic. See Acquired melanocytic 930-931
nevi. Osteoporosis, systemic glucocorticosteroids and,
benign pigmented, and melanoma, screening for, 629 929-930
dysplastic, and melanoma, screening for, 629 Osteosarcoma, in Rothmund-Thomson syndrome, 147
Nevoid basal cell carcinoma syndrome, 113-125 Ovarian fibromas, in nevoid basal cell carcinoma
basal cell carcinoma in, 114 syndrome, 119-120
cardiac fibroma in, 119 Ovarian tumors, in Peutz-Jeghers syndrome, 130
chromosome instability and cellular radiation sensitiv¬
ity in, 120
fetal rhabdomyoma in, 120
general appearance of, 113-114 Palmar and plantar pits, in nevoid basal cell carcinoma
heredity in, 120 syndrome, 115
medulloblastoma in, 118-119 Palmoplantar psoriasis, 773-775
mesenteric cysts in, 119 differential diagnosis of, 773
milia in, 114 diseases associated with, 774